Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Rixa Health

CoreAge Rx
Graded #1

Higher grade

vs+31.299999999999997
Rixa Health
Graded #321

Lower grade

The verdict

CoreAge Rx takes it — 91.8/100 to 60.5/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoreAge Rx +47
92
45
Dose & formulationCoreAge Rx +37
88
51
Clinical oversightCoreAge Rx +8
93
85
Labs & monitoringCoreAge Rx +27
90
63
FulfillmentCoreAge Rx +17
95
78
Contract termsCoreAge Rx +55
96
41
CoreAge Rx · left barRixa Health · right bar

The numbers

MetricCoreAge RxRixa Health
WeighScore91.8/10060.5/100
GradeA−C
Scorecard rank#1#321
Semaglutide$149/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
CoreAge Rx

Graded #1 · A−

Strengths

  • Flat all-in price with no month-two step-up
  • Semaglutide and tirzepatide on one account
  • All 50 states, LegitScript-verified

Where it loses points

  • Not the cheapest sticker price
  • Compounded only
  • Pharmacy partner not yet publicly named
Rixa Health

Graded #321 · C

Strengths

  • Functional-medicine, root-cause clinical approach
  • Compounded and oral semaglutide plus tirzepatide offered
  • Board-certified DO and FNP providers with years of experience
  • Medication bundled with visits into a single price
  • No charge until after approval

Where it loses points

  • No public monthly pricing; quoted only during consultation
  • Relies on compounded GLP-1, which is not FDA-approved as a finished drug
  • A handful of states still listed as coming soon
  • Branded GLP-1 medications are not the primary offering
  • Requires ongoing monthly follow-up commitment

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard